CardioDx Gets Medicare Coverage for Coronary Artery Disease Test | GenomeWeb

NEW YORK (GenomeWeb News) – CardioDx today announced that national Medicare contractor Palmetto GBA will cover the company's Corus CAD gene expression test for coronary artery disease.

Since launching Corus CAD as a laboratory-developed test in 2009, the Palo Alto, Calif.-based cardiovascular genomics testing firm has been collecting clinical utility and cost data to expand insurance reimbursement of the test, which is used to determine which patients have or don't have CAD.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.